There were several interesting research papers, posters, abstracts, and presentations on the advancements in the diagnosis and treatment of lupus at the American College of Rheumatology (ACR) Convergence 2021, including the Great Debate that was about the use of voclosporin vs belimumab as add-on therapy in lupus nephritis.
Karen Costenbader, MD, provides a comprehensive roundup of all the exciting and compelling news and research in lupus, as presented at ACR annual meeting.
Karen Costenbader, MD, MPH, is professor of medicine at Harvard Medical School and holds the Michael Weinblatt, MD, Distinguished Chair in Rheumatology in the Division of Rheumatology Inflammation and Immunity at Brigham and Women’s Hospital (BWH), where she serves as the director of the Lupus Program.
Dr Costenbader’s research investigates the epidemiology and pathogenesis of SLE and rheumatoid arthritis. She is an experienced clinical research mentor for medical students, residents, graduate students in epidemiology, and rheumatology fellows and junior faculty, having trained over 30 doctoral and postdoctoral fellows. She is the principal investigator of the BWH Lupus Registry containing data on more than 2400 patients with SLE.
Dr Costenbader is co-editor of Arthritis and Rheumatology and is the current chair of the Medical-Scientific Advisory Council for the Lupus Foundation of America. She also serves on grant review committees and is a reviewer for multiple journals.